North America Sepsis Diagnostics Market Insights, Future Trends, On-going Demand, Opportunities, Segmentation, and Forecast (2021-2028)
The North America sepsis diagnostics market is expected to grow from US$ 279.06 million in 2021 to US$ 513.33 million by 2028. It is estimated to record a CAGR of 9.1% from 2021 to 2028.
High Incidence of Sepsis due to Increasing Nosocomial Infections Drives North America Sepsis Diagnostics Market
Sepsis, a severe condition, stems from infection and disproportionately impacts immunocompromised individuals, including those receiving chemotherapy, post-splenectomy patients, or those afflicted with AIDS or chronic conditions like diabetes. A major contributor to morbidity and mortality among hospitalized patients are nosocomial infections. The “2020 National and State Healthcare-Associated Infections Progress Report” published by the Centers for Disease Control and Prevention (CDC) in 2021, showed a substantial rise in US healthcare-associated infections between 2019 and 2020. Central line-associated bloodstream infections increased by about 24%, ventilator-associated events by 35%, and Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia by 15%.
The Global Sepsis Alliance (GSA) reports that nearly 26 million people globally develop sepsis each year, resulting in approximately 8 million deaths. Many of these deaths, often a consequence of diarrheal diseases or lower respiratory infections, are preventable with early diagnosis and appropriate clinical management. This high incidence of sepsis and the growing number of bloodstream infections are expected to drive the demand for sepsis diagnostic products, thus boosting the North America sepsis diagnostics market growth during the forecast period.
Download our Sample PDF Report
@ https://www.businessmarketinsights.com/sample/BMIRE00025664
North America Sepsis Diagnostics Strategic Insights
North America Sepsis Diagnostics Strategic Insights provides a data-driven analysis of the industry landscape, encompassing current trends, key players, and regional specificities. These insights offer actionable recommendations, empowering readers to distinguish themselves from competitors by identifying untapped market segments or crafting unique value propositions. Leveraging data analytics, these insights help industry players anticipate market shifts, whether they are investors, manufacturers, or other stakeholders. A future-oriented perspective is crucial, helping stakeholders foresee market changes and position themselves for sustained success in this dynamic region. Ultimately, effective strategic insights enable readers to make informed decisions that drive profitability and achieve their business objectives within the market.
North America Sepsis Diagnostics Market Segmentation
North America Sepsis Diagnostics Market By Product
Instruments
Reagents and Assays
Blood Culture Media
Software
North America Sepsis Diagnostics Market By Technology
Molecular Diagnostics
By Flow Cytometry, Microfluidics, Immunoassay, Biomarkers, Microbiology)
North America Sepsis Diagnostics Market By Method
Automated Diagnostics and Conventional Diagnostics
North America Sepsis Diagnostics Market By Test Type
Point-of-Care Tests and Laboratory Tests
North America Sepsis Diagnostics Market Regions and Countries Covered
North America
US
Canada
Mexico
North America Sepsis Diagnostics Market leaders and key company profiles
Abbott
BD
bioMerieux SA
Danaher (Beckman Coulter)
F. HOFFMANN-LA ROCHE LTD.
Immunexpress Inc.
Luminex Corporation
T2 Biosystems, Inc.
THERMO FISHER SCIENTIFIC INC.
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications